- Switzerland wants stricter intellectual property rules in India that could harm generic drug makers
- Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay Millions in Costs
- Study & video released about the impact of the Mercosur/EU FTA on access to medicines in Brazil
- European FTA pushes for tougher IPR rules under ongoing trade talks with India
- India–EFTA trade talks may make medicines more expensive
Category Archives: Hepatitis C
Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading
By Rupali Mukherjee, The Times of India MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading
Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading
The World Health Organization (WHO) recently reported that over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.
(Paris, October 5th 2016) European Patent Office (EPO) has taken its decision following Doctors of the World – Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
By Giulia Paravicini, Politico| Sept 19, 2016 Italy’s biggest doctors association Fnomceo wants the government to make available generic versions of pricey hepatitis c drugs so more patients can have access to them. “We want to make these drugs available for … Continue reading
A writ petition was filed before the Delhi High Court by I-MAK and DNP+, challenging the grant of patent to costly Hepatitis-C drug, Sofosbuvir. The first hearing for the case was expected take place on 13th September. However, the hearing has … Continue reading